The market already knew the trial had succeeded, but not the size of the win. Cullinan’s current story is a transition from a broad clinical portfolio toward a more consequential phase: partnered zipalertinib is the nearer-term regulatory asset, while its T-cell engagers remain earlier-stage value drivers. The filing confirms that REZILIENT3 had met its primary endpoint, but the full interim dataset is the new information. 〔0〕
| Measure | Zipalertinib + chemotherapy | Chemotherapy alone | Read-through |
|---|---|---|---|
| Median PFS | 14.5 months | 8.5 months | 6.0-month advantage (Summary of Results) |
| PFS hazard ratio | 0.50 | — | 50% lower progression or death risk (Summary of Results) |
| Objective response rate | 65.0% | 40.3% | 24.7-point advantage (Summary of Results) |
| Median duration of response | 14.2 months | 9.9 months | 4.3-month advantage (Summary of Results) |
| Overall-survival hazard ratio | 0.72 | — | Directionally favorable, but only 30% mature (Summary of Results) |
| Grade ≥3 adverse events | 87.1% | 54.4% | Meaningfully higher toxicity burden (Summary of Preliminary Safety and Tolerability) |
The efficacy result is clearly above the clinical success bar. A median PFS improvement from 8.5 to 14.5 months, a hazard ratio of 0.50, higher response rates and longer response duration together make this more than a narrow endpoint win. The benefit also extended to patients with brain metastases, an important subgroup for first-line EGFR-mutated lung cancer. 〔1〕
The main limitation is that the regulatory-quality efficacy signal is stronger than the survival evidence so far. Overall survival points in the right direction, but the hazard ratio’s confidence interval crosses 1.0 and the analysis is only 30% mature. That leaves follow-up and regulatory execution as the remaining steps before this becomes a fully de-risked commercial opportunity.
Safety is a real trade-off, not a reason to overturn the read. Severe adverse events were substantially more common with the combination, driven mainly by hematologic toxicity, although the filing reports no new safety signals and characterizes the profile as generally consistent with the individual agents. Net: this materially advances Cullinan’s partnered-asset narrative from “promising Phase 3 success” to “strong first-line efficacy with a plausible regulatory path,” while leaving overall-survival maturity and treatment tolerability as the key remaining questions. 〔2〕
Read the original 8-K on SEC EDGAR ↗